Try our Advanced Search for more refined results
KING DRUG COMPANY OF FLORENCE, INC vs. CEPHALON, INC., ET AL
Case Number:
2:06-cv-01797
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Akin Gump
- Armstrong Teasdale
- Berger Montague
- Clark Hill
- Cohen Milstein
- Connolly Wells
- Cravath Swaine
- Eckert Seamans
- Faruqi & Faruqi
- Fine Kaplan
- Garwin Gerstein
- Hagens Berman
- Hangley Aronchick
- Harkins Cunningham
- Heim Payne
- Hilliard & Shadowen
- Kaplan Fox
- Kenny Nachwalter
- Kirkland & Ellis
- Lewis Brisbois
- Marcus & Shapira
- Mintz Levin
- Montgomery McCracken
- NastLaw
- Odom & Des Roches
- Radice Law Firm
- Robinson & Cole
- Roetzel & Andress
- Smith Segura
- Sperling & Slater
- Stevens & Lee
- Taus Cebulash
- Troutman Pepper
- Venable LLP
- Volpe Koenig
- White and Williams
- Willkie Farr
- WilmerHale
- Winchester Sellers
- Zelle LLP
Companies
- Cardinal Health Inc.
- Cephalon Inc.
- CVS Health Corp.
- Giant Eagle Inc.
- H.D. Smith LLC
- H‑E‑B LP
- J.M. Smith Corp.
- McKesson Corp.
- Mutual Drug
- Publix Super Markets Inc.
- Ranbaxy
- Rite Aid Corp.
- Rochester Drug Cooperative Inc.
- Safeway Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- The Harvard Drug Group LLC
- The Kroger Co.
Sectors & Industries:
-
December 15, 2015
Provigil Buyers' Per Se Theory Nixed In Pay-For-Delay Row
A Pennsylvania federal judge on Monday said the generic-drug manufacturers accused of accepting $300 million from Cephalon Inc. to delay generic versions of narcolepsy drug Provigil won't face a per se theory of liability at trial for allegedly knowing the patent was unenforceable, as they had no involvement in its procurement.
-
November 20, 2015
Mylan, Ranbaxy Urge Stay Of Provigil Pay-For-Delay Suits
Mylan Inc. and Ranbaxy Laboratories Ltd. on Thursday urged a Pennsylvania federal judge to stay three cases accusing them and others of accepting $300 million from Cephalon Inc. to delay generic versions of its narcolepsy drug Provigil, pending their effort to overturn a class certification order in the Third Circuit.
-
November 06, 2015
Provigil Judge Says Experts Can Testify On Patent Strength
A Philadelphia federal judge ruled Thursday that drugmakers could use evidence at an upcoming pay-for-delay antitrust trial over Provigil about the strength of the narcolepsy drug patent if purchasers argue that the settlement was a bid to shield a weak patent.
-
October 15, 2015
Teva's $512M Provigil Deal Looks Good To Judge
A Pennsylvania federal judge said Thursday that he would approve a $512 million settlement between direct purchasers and Teva Pharmaceutical Industries Ltd. plus subsidiaries Cephalon Inc. and Barr Pharmaceuticals Inc. in pay-for-delay litigation over Cephalon's narcolepsy drug Provigil.
-
September 18, 2015
Provigil Buyers Want $141M In Fees For Cephalon Deal
Direct buyers of Provigil pressed a Pennsylvania federal court Thursday to award them about $141 million in legal fees for their work in securing a $512 million settlement with Teva Pharmaceutical Industries Ltd. and subsidiaries Cephalon Inc. and Barr Pharmaceuticals Inc. in pay-for-delay litigation.
-
September 15, 2015
Provigil Buyers Again Say Class Cert. Order Needs Tweaking
Direct buyers of Provigil pressed a Pennsylvania federal court again Tuesday to modify a class certification order in the pay-for-delay litigation, saying the opposition by generic-drug makers Mylan Pharmaceuticals Inc. and Ranbaxy Pharmaceuticals Inc. runs contrary to basic antitrust principles.
-
September 11, 2015
Mylan, Ranbaxy Slam Bid To Change Provigil Class Cert.
Generic-drug makers Mylan Pharmaceuticals Inc. and Ranbaxy Pharmaceuticals Inc. have urged a Pennsylvania federal judge to reject a request by direct buyers of Provigil to modify a class certification order in the pay-for-delay litigation, saying it clearly lays out the claims and issues that will be tried.
-
August 25, 2015
Provigil Buyers Say Drug Cos. Twisting Class Cert. Order
Direct Provigil buyers told a Pennsylvania federal judge Monday they were worried Mylan Pharmaceuticals Inc. and Ranbaxy Pharmaceuticals Inc. would try to manipulate a class certification order to improperly limit the issues in the pay-for-delay litigation, asking the court to tweak the ruling.
-
August 13, 2015
Pa. Judge Narrows Class In Provigil Pay-For-Delay Suit
A Pennsylvania federal judge on Thursday narrowed the defined class of direct purchasers of Cephalon Inc.'s narcolepsy drug Provigil in a suit accusing Mylan Pharmaceuticals Inc. and Ranbaxy Pharmaceuticals Inc. of making illegal pay-for-delay deals.
-
July 27, 2015
Provigil Buyers Win Class Cert. In Pay-For-Delay Fight
A Pennsylvania federal judge on Monday certified a class of direct purchasers of Cephalon Inc.'s narcolepsy drug Provigil, despite strong objections from the two generic-drug makers accused of inking illegal pay-for-delay deals.
- ← Previous
- 1
- 2
- 3
- 4
- Next →